TDB Backs Acrannolife Genomics to Scale Advanced Genomic Testing Kits

In a major push toward healthcare self-reliance and biotech innovation, the Technology Development Board (TDB), under the Department of Science & Technology (DST), has extended financial support to Acrannolife Genomics Private Limited to establish a cutting-edge manufacturing facility for advanced diagnostic kits.

The project aims to scale up production of homegrown in-vitro diagnostic (IVD) technologies, reducing India's dependence on imported medical diagnostics while strengthening its capacity to tackle critical diseases such as tuberculosis and post-transplant complications.

Strategic Investment in Indigenous Health Technology

The initiative, titled "Indigenizing IVD Innovation", focuses on setting up a state-of-the-art manufacturing facility at the TANSIDCO Industrial Estate in Chennai.

The facility will enable large-scale production of two key diagnostic solutions:

• Trunome GrafAssure – for early detection of organ transplant rejection and infection

• TBFYND – a rapid diagnostic kit for tuberculosis detection

Officials say the project aligns with India's broader Atmanirbhar Bharat (self-reliance) vision, particularly in critical healthcare technologies.

Cutting-Edge Genomics Meets Clinical Need

Acrannolife Genomics is at the forefront of non-invasive diagnostic innovation, leveraging:

• Cell-free DNA (cfDNA) technology

• Loop-mediated isothermal amplification (LAMP) platforms

These technologies allow for faster, more accurate, and less invasive diagnostic testing—an area of growing global demand.

Early Detection of Organ Rejection

The company's flagship product, Trunome GrafAssure, is a breakthrough blood test designed for transplant patients.

Key capabilities include:

• Detecting organ rejection and infections weeks before symptoms appear

• High diagnostic sensitivity and specificity

• Supporting timely medical intervention, potentially improving survival rates

With India witnessing a steady rise in organ transplants, early detection tools are becoming critical to patient outcomes.

Tackling Tuberculosis with Rapid Diagnostics

The second product, TBFYND, targets tuberculosis (TB)—one of India's most pressing public health challenges, accounting for a significant share of global TB cases.

The kit is designed to:

• Deliver rapid and accurate TB detection

• Improve early diagnosis and treatment initiation

• Support national TB elimination goals

Manufacturing Scale-Up to Strengthen Domestic Capacity

With TDB's financial backing, the project will establish a dedicated platform for high-volume manufacturing, ensuring:

• Scalable production of IVD kits

• Standardised and reliable diagnostic workflows

• Reduced reliance on imported technologies

Both products are fully developed in-house, with secured intellectual property and integrated with proprietary software systems for efficient processing and analysis.

Government Push for Affordable and Accessible Diagnostics

TDB Secretary Shri Rajesh Kumar Pathak emphasised that the initiative reflects the government's commitment to translating cutting-edge research into affordable healthcare solutions.

"Advanced manufacturing capabilities in diagnostic technologies will play a vital role in strengthening India's healthcare ecosystem and promoting self-reliance," he said.

The move is expected to:

• Lower costs of diagnostic testing

• Improve access in both urban and rural healthcare settings

• Support India's growing biotech and med-tech sectors

Industry Response: Scaling Innovation to Reach Patients

Promoters of Acrannolife Genomics welcomed the support, stating that it will accelerate:

• Commercial-scale production

• Wider deployment of diagnostic kits

• Access to advanced genomic testing for healthcare providers and patients

A Step Toward Global Competitiveness in Biotech

The initiative positions India to become a global player in molecular diagnostics, a market projected to grow rapidly due to rising demand for precision medicine and early disease detection.

By investing in indigenous innovation and manufacturing, India is not only addressing domestic healthcare needs but also laying the groundwork for export-ready diagnostic solutions.

Conclusion: Bridging Innovation and Impact

The TDB-backed project underscores a critical shift—from research to real-world impact—where innovation is translated into scalable, affordable healthcare solutions.

As India strengthens its domestic biotech ecosystem, initiatives like this are expected to play a pivotal role in delivering accessible, high-quality diagnostics at scale, both nationally and globally.